Flossbach Von Storch SE Sells 26,490 Shares of Becton, Dickinson and Company $BDX

Key Points

• Flossbach Von Storch SE cut its stake in Becton, Dickinson by 16.0%, selling 26,490 shares and leaving it with 138,830 shares valued at about $26.94 million as of the Q4 13F filing.
• Other institutions increased holdings—Vanguard now owns 36.68 million shares (~$7.12 billion) and Wellington added ~5.17 million shares—leaving roughly 86.97% of BDX held by hedge funds and institutional investors.
• Analysts have a consensus rating of Hold with a consensus price target of $189.08; BDX opened at $150.13, recently reported an EPS beat but revenue miss, and the board authorized a $10.0 million share buyback.

Flossbach Von Storch SE lowered its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 16.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,830 shares of the medical instruments supplier's stock after selling 26,490 shares during the quarter. Flossbach Von Storch SE's holdings in Becton, Dickinson and Company were worth $26,943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock worth $7,118,282,000 after purchasing an additional 4,223,149 shares during the last quarter. State Street Corp grew its stake in shares of Becton, Dickinson and Company by 3.4% during the third quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier's stock valued at $2,596,496,000 after buying an additional 459,219 shares during the last quarter. First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 13.8% during the third quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier's stock valued at $1,870,653,000 after buying an additional 1,208,218 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Becton, Dickinson and Company by 3.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier's stock worth $1,841,083,000 after buying an additional 336,110 shares during the period. Finally, Wellington Management Group LLP lifted its stake in shares of Becton, Dickinson and Company by 9,056.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock valued at $979,290,000 after acquiring an additional 5,174,944 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BDX. TD Cowen raised their price target on Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a "hold" rating in a research report on Wednesday, February 11th. Zacks Research upgraded Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a research report on Friday, April 10th. Barclays assumed coverage on Becton, Dickinson and Company in a research note on Tuesday, February 10th. They set an "overweight" rating and a $202.00 price objective for the company. Citigroup decreased their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a "buy" rating on the stock in a research note on Tuesday, February 10th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a "neutral" rating for the company in a report on Tuesday, February 10th. Six equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Hold" and a consensus price target of $189.08.

Becton, Dickinson and Company Stock Down 1.3%

NYSE BDX opened at $150.13 on Tuesday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock has a market capitalization of $42.75 billion, a PE ratio of 24.49, a PEG ratio of 10.82 and a beta of 0.29. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The business's 50-day moving average is $162.67 and its 200 day moving average is $182.74.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.81 by $0.10. The business had revenue of $4.49 billion during the quarter, compared to analysts' expectations of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business's revenue was up 1.6% on a year-over-year basis. During the same quarter last year, the business posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 12.56 earnings per share for the current year.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share repurchase plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares buyback plans are often a sign that the company's management believes its stock is undervalued.

Insider Buying and Selling

In related news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director owned 36,763 shares in the company, valued at $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.